• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤学中的成本效益分析。

Cost-effectiveness analysis in oncology.

作者信息

Earle C C, Coyle D, Evans W K

机构信息

Cancer Care Ontario, Ottawa Regional Cancer Centre, University of Ottawa, Canada.

出版信息

Ann Oncol. 1998 May;9(5):475-82. doi: 10.1023/a:1008292128615.

DOI:10.1023/a:1008292128615
PMID:9653486
Abstract

Physicians are faced with a burgeoning literature of economic studies. However, most physicians have little training in evaluating economic research. Economic studies involve a comparison of the costs and benefits of alternative treatment options. To be of use for medical decision making, they should meet appropriate methodological standards. These include clear specification of the research question and the perspective from which the study is being undertaken, comparison of relevant treatment options, identification and quantification of all important costs and benefits, the use of discounting to allow for time preferences for costs and benefits, and sensitivity analyses to test the robustness of the study's results. Unfortunately, not all adhere to these principles. Physicians need to be able to understand and critically assess the quality of economic studies, and the applicability of the results to their own situation, in order to participate in medical policy decisions.

摘要

医生们面临着数量迅速增长的经济学研究文献。然而,大多数医生在评估经济学研究方面几乎没有接受过培训。经济学研究涉及对替代治疗方案的成本和收益进行比较。为了用于医疗决策,它们应符合适当的方法标准。这些标准包括明确规定研究问题以及开展研究的视角、比较相关治疗方案、识别和量化所有重要的成本和收益、使用贴现来考虑成本和收益的时间偏好,以及进行敏感性分析以检验研究结果的稳健性。不幸的是,并非所有研究都遵循这些原则。为了参与医疗政策决策,医生需要能够理解并批判性地评估经济学研究的质量以及研究结果对自身情况的适用性。

相似文献

1
Cost-effectiveness analysis in oncology.肿瘤学中的成本效益分析。
Ann Oncol. 1998 May;9(5):475-82. doi: 10.1023/a:1008292128615.
2
Systematic overview of cost-utility assessments in oncology.肿瘤学成本效用评估的系统综述
J Clin Oncol. 2000 Sep 15;18(18):3302-17. doi: 10.1200/JCO.2000.18.18.3302.
3
Cost of cancer care: issues and implications.癌症护理费用:问题与影响
J Clin Oncol. 2007 Jan 10;25(2):180-6. doi: 10.1200/JCO.2006.09.6081.
4
Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.将经济分析纳入癌症临床试验:美国国立癌症研究所-美国临床肿瘤学会经济学工作手册
J Natl Cancer Inst Monogr. 1998(24):1-28.
5
American Society of Clinical Oncology guidance statement: the cost of cancer care.美国临床肿瘤学会指导声明:癌症护理的成本
J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.
6
[Methodology of economic assessment: example in oncology].[经济评估方法:肿瘤学实例]
Bull Cancer. 2003 Nov;90(11):939-45.
7
Introduction to health economics for physicians.医生健康经济学导论。
Lancet. 2001 Sep 22;358(9286):993-8. doi: 10.1016/S0140-6736(01)06107-4.
8
Oncology from an HTA and Health Economic Perspective.从卫生技术评估和卫生经济学角度看肿瘤学
Recent Results Cancer Res. 2019;213:25-38. doi: 10.1007/978-3-030-01207-6_3.
9
Enlightened oncologists can provide quality cancer care at reduced costs.开明的肿瘤学家能够以降低的成本提供高质量的癌症护理。
J Surg Oncol. 2014 Nov;110(6):643-4. doi: 10.1002/jso.23746. Epub 2014 Aug 13.
10
Methodological approaches to pharmaco-economics.药物经济学的方法学途径。
Fundam Clin Pharmacol. 1994;8(2):101-7. doi: 10.1111/j.1472-8206.1994.tb00786.x.

引用本文的文献

1
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.意大利威尼托地区纳武利尤单抗或卡博替尼治疗转移性肾细胞癌(mRCC)的真实世界研究:AMOUR 研究结果。
Target Oncol. 2022 Jul;17(4):467-474. doi: 10.1007/s11523-022-00892-z. Epub 2022 Jun 25.
2
Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.洛拉替尼作为未治疗的晚期间变性淋巴瘤激酶阳性非小细胞肺癌一线治疗的成本效益
Front Oncol. 2021 May 28;11:684073. doi: 10.3389/fonc.2021.684073. eCollection 2021.
3
Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System.
评估 EGFR 酪氨酸激酶抑制剂在巴西统一医疗保健体系下治疗转移性非小细胞肺癌的成本效益的不同模型。
J Bras Pneumol. 2020;46(4):e20180255. doi: 10.36416/1806-3756/e20180255. Epub 2020 Jun 1.
4
Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study.巴西公共医疗系统中因无法获得抗表皮生长因子受体酪氨酸激酶抑制剂用于肺癌治疗而未挽救的潜在生命年:预算影响及改善可及性的策略。一项药物经济学研究。
Sao Paulo Med J. 2019 Nov-Dec;137(6):505-511. doi: 10.1590/1516-3180.2018.0256170919.
5
Cost-effectiveness and affordability of anticancer treatment in Brazil.巴西抗癌治疗的成本效益与可负担性
Ecancermedicalscience. 2020 Jan 20;14:ed96. doi: 10.3332/ecancer.2020.ed96. eCollection 2020.
6
Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.日本的抗癌药物成本与临床获益之间缺乏相关性。
Cancer Sci. 2018 Dec;109(12):3896-3901. doi: 10.1111/cas.13831. Epub 2018 Nov 27.
7
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.奥希替尼一线治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的成本效果分析。
JAMA Oncol. 2018 Aug 1;4(8):1080-1084. doi: 10.1001/jamaoncol.2018.1395.
8
Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan.日本分子靶向抗癌药物的定量药物经济学分析。
Daru. 2013 May 25;21(1):40. doi: 10.1186/2008-2231-21-40.
9
Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.贝伐珠单抗治疗晚期癌症患者的安全性:一项随机对照试验的荟萃分析。
Oncologist. 2010;15(11):1179-91. doi: 10.1634/theoncologist.2009-0155. Epub 2010 Nov 2.
10
Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.通过可控纳米颗粒团聚制备的联合化疗干粉气雾剂。
Pharm Res. 2009 Jul;26(7):1752-63. doi: 10.1007/s11095-009-9886-2. Epub 2009 May 5.